FDA Streamlines Early-Stage IND Submissions and Late-Stage Trial Evidence Standards
- FDA proposes Expedited IND pilot program enabling drug sponsors to partner with academic medical centers and contract research organizations to shorten pre-IND timelines and reduce clinical holds.
- New Phase 1 CMC guidance clarifies phase-appropriate manufacturing data requirements, potentially saving sponsors 6–12 months of development time before first-in-human trials.
- FDA revised substantial-evidence guidance to permit reliance on one rigorous pivotal trial plus confirmatory data for drug approval, reflecting advances in biological understanding and data availability.
Operational Impact
CROs offering Phase 1 regulatory strategy and IND preparation services can now position expedited IND partnerships as a core offering, while those supporting late-stage trial design should prepare clients for single-pivotal-trial pathways under the revised effectiveness guidance.
Source: FDA What's New Drugs RSS